A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

NCT02134834 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Bacterial Infections

Interventions

DRUG: OP0595
DRUG: Placebo

Sponsor

Meiji Seika Pharma Co., Ltd.